In a basement lab at University Medical Center Groningen, researchers have spent the better part of a decade coaxing diamond nanoparticles to do something nature never intended: spy on the molecular chaos inside living cells.
The payoff arrived this month. QT Sense, the Dutch startup that emerged from that work in February 2024, closed a €4 million financing round to commercialize what amounts to a quantum-powered microscope for oxidative stress—those destructive free radicals that drive everything from cancer progression to male infertility. It's a market worth somewhere between $700 million and $1.4 billion annually, depending on whose numbers you trust, but one where the measurement tools have long frustrated the scientists who rely on them.
The February 2026 round brought €3 million in seed equity, led by Cottonwood Technology Fund, with backing from QDNL Participations and a handful of angels who evidently believe in the marriage of quantum mechanics and cell biology. Add another €0.6 million from the ONCO-Q grant program and €0.4 million through the Netherlands' Quantum Forward Challenge, and QT Sense has now pulled in roughly €10 million since launch. That includes a €6 million haul last February mixing equity with Interreg Europe grants.
For a company built on fluorescent nanodiamonds and nitrogen-vacancy defects—concepts that sound ripped from a physics dissertation—the momentum is notable. Then again, so is the technical challenge.
The Measurement Gap That Won't Close
Free radicals are slippery targets. These reactive oxygen species flicker through cellular machinery in nanoseconds, orchestrating immune responses, signaling metabolic shifts, and when things go wrong, killing cells outright. Oncologists know oxidative stress fuels tumor growth. Fertility specialists suspect it tanks sperm quality. Immunologists track it in sepsis.
Yet catching radicals in the act has proven maddeningly difficult. Standard fluorescent probes like DCFDA light up in the presence of reactive oxygen, sure, but they also light up when they shouldn't, plagued by artifacts and dubious specificity. Electron paramagnetic resonance spectroscopy offers precision but requires bulk samples—forget watching a single cell do its thing in real time.
The industry has made peace with imperfect tools, in part because nothing better existed. The global oxidative stress assay market is projected to double or triple by the early 2030s, hitting somewhere between $2 billion and $3.1 billion. That growth reflects demand, not satisfaction.
QT Sense's answer is a platform called Quantum Nuova, and it leans on a quirk of quantum physics that took years to tame. Nitrogen-vacancy centers—lattice defects in synthetic diamond crystals—act as exquisitely sensitive magnetic field detectors. When free radicals swirl nearby, their unpaired electrons create magnetic noise. The NV centers register that noise through changes in fluorescence lifetime, a readout technique called T1 relaxometry.
The system detects radical concentrations down to the nanomolar range with spatial resolution approaching one micrometer. It takes about 15 minutes per run and handles 96 samples at once. More important, it works in live cells—no fixing, no killing, no wondering whether the measurement destroyed the very biology you're trying to observe.
"The goal is to get robust, scalable platforms into real labs," CEO Dr. Deepak Veeregowda said after the seed close, his phrasing careful in the way of founders who've spent years translating academic breakthroughs into products that someone might actually buy. Early-access placements are underway with oncology and drug discovery partners, though Veeregowda declined to name them.
A Long Gestation
The science didn't materialize overnight. Prof. Dr. Romana Schirhagl's group at UMCG spent a decade refining nanodiamond relaxometry for biological systems, publishing steadily along the way. Her team demonstrated radical detection in primary human dendritic cells, tracked macrophage battles with Staphylococcus aureus, and implicated NOX5 enzymes in boar sperm capacitation—an application that might matter more to fertility clinics than most quantum physicists would guess.
A 2020 review in ACS Sensors and a 2022 account in Accounts of Chemical Research laid the scientific foundation. By 2024, Schirhagl and Veeregowda figured the technology was ready, or as ready as it would get, to leave the university.
The first Quantum Nuova system landed back at UMCG, supporting clinical validation through the ONCO-Q consortium—a colorectal cancer project bankrolled by roughly €2 million from the Just Transition Fund. Partners include the University of Groningen and Healthy Ageing Network Northern Netherlands. Additional research threads run through osteoarthritis diagnostics, real-time semen analysis for male fertility clinics, and early sepsis detection via immune cell stress markers.
Schirhagl, in an August 2025 podcast, sketched a timeline toward clinical use by 2030. Perhaps that's optimistic. The company's current positioning is research-use-only. Moving to an in-vitro diagnostic under the EU's IVDR framework, or navigating U.S. regulatory pathways, would demand clinical evidence and notified-body approvals—a longer slog than rolling out research instruments.
But then, hardware companies in deep tech rarely move fast.
The Quantum-Bio Gold Rush
QT Sense enters a moment when quantum sensing is migrating from physics labs into applied biology, though the path remains uneven. A 2023 Nature Reviews Physics survey identified two leading biomedical quantum sensing platforms: optically pumped atomic magnetometers and nitrogen-vacancy centers in diamond.
OPMs have gained clinical traction through magnetoencephalography. FieldLine, Cerca, MEGIN, and Compumedics installed new OPM-MEG systems in 2025 and 2026 for epilepsy, dementia, and ADHD research. NVision Imaging raised $30 million in 2023 to deploy quantum-assisted hyperpolarization for metabolic MRI, securing partnerships with Siemens and placements at major cancer centers. Quantum Diamond Technologies, born at Harvard's Wyss Institute, uses NV magnetic imaging for ultrasensitive biomarker detection.
Adamas Nanotechnologies supplies functionalized fluorescent nanodiamonds and ODMR instrumentation to researchers studying temperature, magnetic fields, and oxidative stress. The company has carved out a niche serving scientists who want the raw materials but prefer to build their own systems.
Market sizing gets speculative this early. The broader quantum sensor market sat around $415 million in 2025 and is forecast to hit $1.3 billion by 2035—annual growth near 12 percent. The NV-center diamond segment specifically ranged from $186 million to $413 million in 2024, with projections climbing to $890 million to $1.43 billion by 2033. That's compound annual growth between 17 and 19 percent, assuming the technology delivers on its promise.
Meanwhile, single-cell analysis tools represent a $4 billion to $6 billion market expected to reach $11 billion to $19 billion by the early 2030s. Labs already spending heavily on flow cytometers, high-content imaging systems, and metabolic analyzers might find budget room for instruments offering functional readouts beyond transcriptomics and proteomics.
Might. The value proposition still needs proving in the field.
Technical Realities
Diamond-NV biosensing isn't turnkey. Near-surface NV centers face charge stability and coherence challenges. Background fluorescence from biological substrates threatens to drown the diamond signal, though recent advances in time-gated and pulsed excitation help. Nanoparticle heterogeneity and the need for standardized ensemble T1 analysis complicate data processing.
A December 2024 study from Okayama University reported higher-quality NV nanodiamonds with longer coherence times and reduced cytotoxicity, addressing some materials constraints. Progress, but incremental.
Biological specificity presents another layer. T1 relaxometry senses total magnetic noise from unpaired electrons—it doesn't inherently identify which radical species is present. Attribution may require orthogonal assays or pharmacological controls. Reviews comparing NV sensing to conventional ROS probes note this trade-off: the method avoids artifacts plaguing fluorescent dyes but trades chemical specificity for spatial and temporal resolution.
In vivo applications remain largely exploratory. Demonstrated examples include magnetocardiography in rats, intravital nanodiamond thermometry in a rodent mastitis model, and temperature sensing in C. elegans. For human use, light penetration, tissue motion, and photonics integration pose engineering challenges that will likely confine early clinical applications to ex vivo or biopsy-based workflows. Perhaps that's enough for now.
The Dutch Advantage
QT Sense benefits from geography. The Netherlands ranks second globally in quantum technology development, with private investment surging 1,600 percent between 2019 and 2025, according to ecosystem reports. Quantum Delta NL operates a €60 million fund through QDNL Participations and runs competitive programs like the Quantum Forward Challenge, which allocated funds to QT Sense for collaborative validation in 2026.
Cottonwood Technology Fund's decision to lead the seed round reflects conviction in deep-tech spinouts with decade-long R&D foundations. Veeregowda emphasized that the investor's experience with hardware-intensive, long-cycle businesses aligned with QT Sense's trajectory. This isn't software with rapid iteration. It's an instrument company building a platform for longitudinal, label-free cellular assays—a fundamentally different beast.
What Happens Next
The near-term roadmap centers on early-access placements and research-use-only market penetration. Cancer researchers studying metabolic shifts, fertility clinics seeking real-time sperm function tests, and immunologists tracking sepsis biomarkers represent the customer base. The ONCO-Q colorectal cancer validation project will generate clinical data, though translating that into a diagnostic product requires navigating EU IVDR requirements or, in the U.S., a laboratory-developed test pathway under CLIA oversight.
Regulatory clarity remains uncertain. The FDA's 2024 LDT rule was vacated in March 2025 and formally rescinded in September. Whether that helps or hinders companies like QT Sense is anyone's guess.
Broader technical evolution points toward parallelized NV arrays for higher throughput, all-optical or microwave-free readout schemes to simplify instrumentation, and integration with microfluidics or AI analytics. Reviews anticipate single-cell metabolomics, label-free drug screening, and live-tissue functional imaging as future applications, contingent on continued materials improvements and readout innovations.
Whether quantum biosensing achieves widespread adoption depends on value proposition clarity. Research labs already spending hundreds of thousands on incumbent tools will evaluate Quantum Nuova against established systems. The pitch—subcellular oxidative stress mapping in live samples, with temporal dynamics and minimal perturbation—targets gaps those systems can't fill. For pharmaceutical companies optimizing antioxidant therapies or oncologists parsing tumor microenvironments, that differentiation may justify the investment.
Or it may not. Markets have a way of humbling even the most elegant technologies.
But the convergence of quantum physics and cell biology is no longer theoretical. It's instrumented, funded, and entering labs where questions about radical biology have waited years for better answers. QT Sense's €4 million raise and clinical consortium partnerships suggest the market is ready to find out if diamonds can do more than sparkle—they might just illuminate how cells live and die.
Whether that illumination translates to revenue is the next chapter.
